Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Recommendation of “Hold” from Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been given an average rating of “Hold” by the six brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $70.75.

A number of analysts have recently issued reports on the company. Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Canaccord Genuity Group reduced their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Finally, Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president directly owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds have recently modified their holdings of the stock. Pacer Advisors Inc. increased its stake in shares of Prestige Consumer Healthcare by 116.5% in the first quarter. Pacer Advisors Inc. now owns 2,866 shares of the company’s stock worth $170,000 after acquiring an additional 1,542 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of Prestige Consumer Healthcare in the first quarter worth $236,000. Amundi increased its stake in shares of Prestige Consumer Healthcare by 18.1% in the first quarter. Amundi now owns 9,252 shares of the company’s stock worth $548,000 after acquiring an additional 1,421 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Prestige Consumer Healthcare by 19.4% in the first quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the company’s stock worth $91,000 after acquiring an additional 249 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Prestige Consumer Healthcare by 21.4% in the first quarter. California State Teachers Retirement System now owns 57,310 shares of the company’s stock worth $3,397,000 after acquiring an additional 10,117 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Price Performance

PBH opened at $46.99 on Friday. The stock has a fifty day moving average of $51.43 and a 200-day moving average of $59.24. The firm has a market capitalization of $2.23 billion, a P/E ratio of 12.02, a PEG ratio of 1.48 and a beta of 0.35. Prestige Consumer Healthcare has a 12-month low of $42.62 and a 12-month high of $85.29. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The business had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. Prestige Consumer Healthcare’s revenue for the quarter was down 5.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Equities analysts forecast that Prestige Consumer Healthcare will post 4.45 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).